Primary |
Iron Deficiency Anaemia |
32.0% |
Drug Use For Unknown Indication |
23.9% |
Anaemia |
15.1% |
Iron Deficiency |
8.6% |
Blood Pressure |
3.0% |
Hypertension |
2.4% |
Pain |
1.9% |
Renal Failure Chronic |
1.6% |
Supplementation Therapy |
1.6% |
Premedication |
1.3% |
Thrombosis Prophylaxis |
1.3% |
Crohn's Disease |
1.1% |
Gastric Disorder |
1.1% |
Erysipelas |
0.8% |
Iron Deficiency Anemia |
0.8% |
Malabsorption |
0.8% |
Prophylaxis |
0.8% |
Renal Disorder |
0.8% |
Anemia |
0.5% |
Anxiety |
0.5% |
|
Vomiting |
28.2% |
Urticaria |
10.0% |
Syncope |
7.1% |
Dyspnoea |
4.7% |
Nausea |
4.7% |
Paraesthesia |
4.7% |
Oedema Peripheral |
4.1% |
Urinary Incontinence |
4.1% |
Swollen Tongue |
3.5% |
Faecal Incontinence |
2.9% |
Pruritus |
2.9% |
Rash |
2.9% |
Throat Tightness |
2.9% |
Unresponsive To Stimuli |
2.9% |
Death |
2.4% |
Hypotension |
2.4% |
Loss Of Consciousness |
2.4% |
Oxygen Saturation Decreased |
2.4% |
Tachycardia |
2.4% |
Wrong Technique In Drug Usage Process |
2.4% |
|
Secondary |
Drug Use For Unknown Indication |
26.8% |
Iron Deficiency Anaemia |
17.8% |
Premedication |
10.3% |
Blood Pressure |
5.6% |
Supplementation Therapy |
4.7% |
Antidepressant Therapy |
3.8% |
Hypertension |
3.8% |
Iron Deficiency |
3.8% |
Pain |
3.8% |
Anaemia |
2.8% |
Foetal Exposure During Pregnancy |
2.8% |
Malabsorption |
2.3% |
Gastrooesophageal Reflux Disease |
1.9% |
Prophylaxis |
1.9% |
Thrombosis Prophylaxis |
1.9% |
Depression |
1.4% |
Product Used For Unknown Indication |
1.4% |
Renal Failure Chronic |
1.4% |
Anxiety |
0.9% |
Back Pain |
0.9% |
|
Vomiting |
22.4% |
Weight Decreased |
16.3% |
Faecal Incontinence |
8.2% |
Urinary Incontinence |
8.2% |
Oxygen Saturation Decreased |
6.1% |
Stomatitis |
6.1% |
Blood Urea Increased |
4.1% |
Pruritus |
4.1% |
Cardiac Failure Congestive |
2.0% |
Cyanosis |
2.0% |
Death |
2.0% |
Dizziness |
2.0% |
Dyspnoea |
2.0% |
Extravasation |
2.0% |
Hypotonia |
2.0% |
Joint Swelling |
2.0% |
Klebsiella Bacteraemia |
2.0% |
Loss Of Consciousness |
2.0% |
Off Label Use |
2.0% |
Presyncope |
2.0% |
|
Concomitant |
Product Used For Unknown Indication |
59.4% |
Drug Use For Unknown Indication |
10.4% |
Nuclear Magnetic Resonance Imaging |
6.6% |
Hyperparathyroidism Secondary |
4.2% |
Hypertension |
4.1% |
Angiogram |
2.7% |
Anaemia |
2.1% |
Renal Failure Chronic |
2.0% |
Pain |
1.5% |
Iron Deficiency Anaemia |
1.0% |
Hyperparathyroidism |
1.0% |
Nausea |
1.0% |
Nuclear Magnetic Resonance Imaging Brain |
0.6% |
Pneumonia |
0.6% |
Renal Failure |
0.6% |
Hyperphosphataemia |
0.5% |
Supplementation Therapy |
0.5% |
Dialysis |
0.5% |
Computerised Tomogram |
0.4% |
Diarrhoea |
0.4% |
|
Drug Ineffective |
11.5% |
Skin Tightness |
11.0% |
Therapeutic Response Decreased |
7.0% |
Death |
6.0% |
Shunt Occlusion |
6.0% |
Shunt Thrombosis |
4.5% |
Syncope |
4.5% |
Cardiac Arrest |
4.0% |
Cardiac Failure |
4.0% |
Nephrogenic Anaemia |
4.0% |
Pneumonia |
4.0% |
Renal Failure Acute |
4.0% |
Subcutaneous Nodule |
4.0% |
Thrombocytopenia |
4.0% |
Vertigo |
4.0% |
Weight Decreased |
4.0% |
Anaemia |
3.5% |
General Physical Health Deterioration |
3.5% |
Hospitalisation |
3.5% |
Pericardial Effusion |
3.0% |
|